Michael Bartholomew

Executive, Board of Director, Founder and Serial Entrepreneur

Michael Bartholomew is a prominent executive in the medical technology sector, currently serving as the Executive Vice President (EVP) and Chief Commercial Officer at Promaxo, a company specializing in advanced MRI technology for office-based procedures. He is also a Co-Founder and Inside Director on the Board of Directors at Promaxo, where he plays a crucial role in shaping the company's go-to-market strategies and managing partner relationships.1 2 3

Professional Background

Bartholomew has extensive experience in the medical devices and biopharmaceutical industries, with a focus on product development and commercialization across nearly twenty therapeutic areas. His career includes significant roles such as:

Principal at Porzio Life Sciences, where he oversaw global commercialization efforts.
Vice President of Sales & Marketing at Dohmen Life Science Services, where he launched several successful initiatives leading to sustained sales growth.
Senior Sales Leader at Pfizer, where he was responsible for significant revenue growth within his territory.1 2

Education

He holds a Master of Science in Administration from Central Michigan University and a Bachelor of Arts in Economics from Indiana University. His educational background complements his extensive practical experience in the healthcare sector.1 2

Military Service

In addition to his corporate achievements, Bartholomew is a decorated veteran of the U.S. Air Force, where he served as a combat aviator, achieving the rank of Captain.1 2

Current Endeavors

At Promaxo, Bartholomew is instrumental in commercializing innovative MRI technology that aims to improve patient care by enabling earlier diagnosis and intervention for various conditions. His leadership is characterized by a commitment to advancing medical technology through strategic partnerships and market insights.3 4

In addition to his role at Promaxo, he is involved with several other organizations, including serving on the Board of Directors for Achelios Therapeutics and as an advisor for neuro42, which focuses on integrating MRI with robotics and AI technologies.2